RU2017105161A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2017105161A3 RU2017105161A3 RU2017105161A RU2017105161A RU2017105161A3 RU 2017105161 A3 RU2017105161 A3 RU 2017105161A3 RU 2017105161 A RU2017105161 A RU 2017105161A RU 2017105161 A RU2017105161 A RU 2017105161A RU 2017105161 A3 RU2017105161 A3 RU 2017105161A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/082602 | 2014-07-21 | ||
| CN2014082602 | 2014-07-21 | ||
| CNPCT/CN2014/090500 | 2014-11-06 | ||
| CN2014090500 | 2014-11-06 | ||
| PCT/US2015/041337 WO2016014535A1 (en) | 2014-07-21 | 2015-07-21 | Treatment of cancer using a cll-1 chimeric antigen receptor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017105161A RU2017105161A (ru) | 2018-08-21 |
| RU2017105161A3 true RU2017105161A3 (ru) | 2019-04-01 |
| RU2741120C2 RU2741120C2 (ru) | 2021-01-22 |
Family
ID=53761606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017105161A RU2741120C2 (ru) | 2014-07-21 | 2015-07-21 | Лечение рака с использованием химерного антигенного рецептора cll-1 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10568947B2 (ru) |
| EP (1) | EP3171882A1 (ru) |
| JP (2) | JP6736540B2 (ru) |
| KR (1) | KR20170037625A (ru) |
| CN (1) | CN107109420A (ru) |
| AR (1) | AR101829A1 (ru) |
| AU (2) | AU2015292811B2 (ru) |
| BR (1) | BR112017000939A2 (ru) |
| CA (1) | CA2955465A1 (ru) |
| CO (1) | CO2017000506A2 (ru) |
| IL (1) | IL250116B (ru) |
| MX (1) | MX2017001013A (ru) |
| RU (1) | RU2741120C2 (ru) |
| SG (2) | SG10201913782UA (ru) |
| TW (1) | TWI718992B (ru) |
| WO (1) | WO2016014535A1 (ru) |
Families Citing this family (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150320799A1 (en) | 2012-12-20 | 2015-11-12 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| JP2016537345A (ja) | 2013-11-13 | 2016-12-01 | ノバルティス アーゲー | 免疫応答を増強するためのｍＴＯＲ阻害剤 |
| CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| FI3888674T3 (fi) | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| IL303247A (en) | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| CA2973529A1 (en) * | 2015-01-26 | 2016-08-04 | Cellectis | Cll1-specific multi-chain chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| CN107531805A (zh) | 2015-03-05 | 2018-01-02 | 弗雷德哈钦森癌症研究中心 | 免疫调节融合蛋白及其用途 |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| CN108473957B (zh) | 2015-04-17 | 2024-07-16 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN107847491A (zh) | 2015-05-20 | 2018-03-27 | 诺华公司 | 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合 |
| US20180171298A1 (en) | 2015-06-30 | 2018-06-21 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| JP2018536436A (ja) | 2015-12-04 | 2018-12-13 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| CN109153975A (zh) | 2015-12-28 | 2019-01-04 | 诺华股份有限公司 | 制备嵌合抗原受体表达细胞的方法 |
| JP2019500394A (ja) | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
| WO2017125897A1 (en) * | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| EP3432924A1 (en) | 2016-03-23 | 2019-01-30 | Novartis AG | Cell secreted minibodies and uses thereof |
| AU2017244108B2 (en) * | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| PL3436079T3 (pl) | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| PE20190356A1 (es) * | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| SI3443096T1 (sl) | 2016-04-15 | 2023-07-31 | Novartis Ag | Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev |
| US12048718B2 (en) | 2016-06-07 | 2024-07-30 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| CN120285179A (zh) | 2016-07-15 | 2025-07-11 | 诺华股份有限公司 | 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征 |
| IL264486B2 (en) | 2016-07-28 | 2025-04-01 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| SG11201900885VA (en) | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| WO2018057915A1 (en) * | 2016-09-23 | 2018-03-29 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| JP2019532672A (ja) | 2016-09-28 | 2019-11-14 | ノバルティス アーゲー | 多孔質膜系巨大分子送達システム |
| JP6887492B6 (ja) * | 2016-10-04 | 2021-07-14 | プレシジョン バイオサイエンシズ，インク． | 遺伝子改変細胞で使用するための共刺激ドメイン |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| ES2978486T3 (es) * | 2016-10-21 | 2024-09-13 | Ose Immunotherapeutics | Métodos para promover la respuesta de linfocitos T |
| CN110114070A (zh) | 2016-11-23 | 2019-08-09 | 诺华公司 | 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法 |
| EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| US20200048359A1 (en) | 2017-02-28 | 2020-02-13 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| BR112019017751A2 (pt) | 2017-02-28 | 2020-04-07 | Vor Biopharma, Inc. | composições e métodos de inibição de proteínas de linhagem específica |
| EP3595706A1 (en) | 2017-03-17 | 2020-01-22 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
| MX2019011272A (es) | 2017-03-22 | 2019-10-24 | Novartis Ag | Composiciones y metodos para inmunooncologia. |
| WO2019000146A1 (zh) * | 2017-06-26 | 2019-01-03 | 深圳市博奥康生物科技有限公司 | 一种人程序性死亡受体1基因的siRNA及其应用 |
| BR112020007576A2 (pt) | 2017-10-18 | 2020-09-24 | Novartis Ag | composições e métodos para degradação de proteína seletiva |
| MX2020004229A (es) | 2017-10-25 | 2020-07-22 | Novartis Ag | Metodos de produccion de celulas que expresan receptores antigenicos quimericos. |
| US20210179709A1 (en) | 2017-10-31 | 2021-06-17 | Novartis Ag | Anti-car compositions and methods |
| TW201925782A (zh) * | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
| EP3717008A1 (en) * | 2017-12-01 | 2020-10-07 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
| CN111492243B (zh) * | 2017-12-21 | 2024-11-01 | 豪夫迈·罗氏有限公司 | 用于新颖抗原结合模块的特异性测试的car-t细胞测定法 |
| JP7394058B2 (ja) * | 2017-12-21 | 2023-12-07 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ |
| WO2019139888A1 (en) * | 2018-01-09 | 2019-07-18 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting clec12a-expressing cancers |
| AU2019209432A1 (en) | 2018-01-22 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for CAR T cells |
| CN111936518A (zh) | 2018-02-06 | 2020-11-13 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car |
| WO2019165237A1 (en) | 2018-02-23 | 2019-08-29 | Endocyte, Inc. | Sequencing method for car t cell therapy |
| AU2019231205A1 (en) * | 2018-03-06 | 2020-09-24 | The Trustees Of The University Of Pennsylvania | Prostate-specific membrane antigen cars and methods of use thereof |
| EP3775902B1 (en) * | 2018-04-04 | 2023-02-22 | F. Hoffmann-La Roche AG | Diagnostic assays to detect tumor antigens in cancer patients |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US12448426B2 (en) * | 2018-05-17 | 2025-10-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with MYD88 and CD40 costimulatory domains |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| CN108866088B (zh) * | 2018-06-20 | 2023-06-09 | 上海恒润达生生物科技股份有限公司 | 靶向cll-1嵌合抗原受体及其用途 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| SG11202101994XA (en) | 2018-08-28 | 2021-03-30 | Vor Biopharma Inc | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| ES3042082T3 (en) | 2018-08-31 | 2025-11-18 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CN112789293B (zh) * | 2018-09-10 | 2024-05-10 | 南京传奇生物科技有限公司 | 针对cll1的单结构域抗体及其构建体 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3114707A1 (en) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| CN113039205B (zh) * | 2018-10-26 | 2024-03-22 | 科济生物医药（上海）有限公司 | 靶向cll1的抗体及其应用 |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12227566B2 (en) | 2018-12-05 | 2025-02-18 | Hedgehog, Inc. | Endothelin receptor type a activity regulating antibody |
| KR102335799B1 (ko) * | 2018-12-05 | 2021-12-08 | 주식회사 헤지호그 | 엔도텔린 수용체 a 활성 조절 항체 |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| WO2020128972A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| ES2982474T3 (es) | 2019-02-15 | 2024-10-16 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidin-1,6-diona sustituidos y usos de estos |
| US20220088075A1 (en) | 2019-02-22 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| KR20210134339A (ko) | 2019-02-25 | 2021-11-09 | 노파르티스 아게 | 바이러스 전달을 위한 메조다공성 실리카 입자 조성물 |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| MA55305A (fr) | 2019-03-11 | 2022-01-19 | Janssen Biotech Inc | Anticorps bispécifiques anti-v béta 17/anti-cd123 |
| EP3946432A4 (en) * | 2019-03-27 | 2023-04-05 | Research Institute at Nationwide Children's Hospital | GENERATION OF PRIMARY CHIMERA ANTIGEN RECEPTOR (CAR) NK CELLS FOR CANCER IMMUNOTHERAPY USING A COMBINATION OF CAS9/RNP AND AAV VIRUS |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| US12043667B2 (en) | 2019-05-04 | 2024-07-23 | Inhibrx Biosciences, Inc. | CLEC12a binding polypeptides and uses thereof |
| CA3148027A1 (en) | 2019-05-08 | 2020-11-12 | 2Seventy Bio, Inc. | Cll-1 targeted immunotherapies |
| EP3983538A1 (en) | 2019-06-12 | 2022-04-20 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021026266A1 (en) * | 2019-08-05 | 2021-02-11 | Distributed Bio, Inc. | Antigen binding molecules and methods of screening thereof |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| CA3154389A1 (en) * | 2019-09-13 | 2021-03-18 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting cd371 and uses thereof |
| CA3163104A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
| MX2022007759A (es) | 2019-12-20 | 2022-07-19 | Novartis Ag | Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico. |
| WO2021158960A1 (en) * | 2020-02-07 | 2021-08-12 | Ellebedy Ali | Antibodies protective against influenza b |
| BR112022016633A2 (pt) | 2020-02-27 | 2022-12-13 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
| US20230256017A1 (en) | 2020-02-27 | 2023-08-17 | Jennifer Brogdon | Methods of making chimeric antigen receptor-expressing cells |
| GB202005216D0 (en) * | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| MX2022015852A (es) | 2020-06-23 | 2023-01-24 | Novartis Ag | Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| EP4188549A1 (en) | 2020-08-03 | 2023-06-07 | Novartis AG | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230302155A1 (en) | 2020-08-21 | 2023-09-28 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| WO2022056197A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
| US20220089737A1 (en) * | 2020-09-11 | 2022-03-24 | Janssen Biotech, Inc. | Multi-specific immune targeting molecules and uses thereof |
| WO2022056192A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| CN118056008A (zh) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | 病毒载体生产系统 |
| CN113461818B (zh) * | 2021-06-30 | 2022-01-21 | 徐州医科大学 | 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法 |
| US20250082681A1 (en) * | 2021-07-30 | 2025-03-13 | Nanjing Legend Biotech Co., Ltd. | Antibodies against cll1 and constructs thereof |
| WO2023021477A1 (en) | 2021-08-20 | 2023-02-23 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
| US12279845B2 (en) | 2021-10-18 | 2025-04-22 | Cilag Gmbh International | Cable-driven actuation system for robotic surgical tool attachment |
| WO2023201238A1 (en) * | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
| CN119816591A (zh) * | 2022-04-29 | 2025-04-11 | 贝勒医学院 | 末端脱氧核苷酰转移酶抗体及其用途 |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| WO2023225641A2 (en) * | 2022-05-20 | 2023-11-23 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods for targeting clec12a-expressing cancers |
| EP4577234A1 (en) | 2022-08-26 | 2025-07-02 | Kite Pharma, Inc. | Improving immune cell function |
| GB202214132D0 (en) | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
| WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
| WO2024149225A1 (zh) * | 2023-01-10 | 2024-07-18 | 合源康华医药科技(北京)有限公司 | 一种人源化cll1抗体、嵌合抗原受体及其应用 |
| GB202301949D0 (en) | 2023-02-10 | 2023-03-29 | Coding Bio Ltd | CLL1 and/or CD33 binding molecules |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025137473A1 (en) * | 2023-12-20 | 2025-06-26 | Dianthus Therapeutics Opco, Inc. | Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same |
Family Cites Families (180)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5906936A (en) | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US7049136B2 (en) | 1991-03-07 | 2006-05-23 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
| DE69528894T2 (de) | 1994-05-02 | 2003-03-27 | Bernd Groner | Bifunktionelles protein, herstellung und verwendung |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6103521A (en) | 1995-02-06 | 2000-08-15 | Cell Genesys, Inc. | Multispecific chimeric receptors |
| WO1996025953A1 (en) | 1995-02-24 | 1996-08-29 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| GB9526131D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Recombinant chimeric receptors |
| US5874240A (en) | 1996-03-15 | 1999-02-23 | Human Genome Sciences, Inc. | Human 4-1BB receptor splicing variant |
| US5792648A (en) | 1996-07-31 | 1998-08-11 | Incyte Pharmaceuticals, Inc. | Human macrophage antigen |
| US20030060444A1 (en) | 1997-06-25 | 2003-03-27 | Celltech Therapeutics, Ltd. | Cell activation process and reagents therefor |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| JP2002541845A (ja) | 1999-04-16 | 2002-12-10 | セルテック セラピューティックス リミテッド | 合成膜貫通成分 |
| GB9925848D0 (en) | 1999-11-01 | 1999-12-29 | Celltech Therapeutics Ltd | Biological products |
| CN1427891A (zh) | 2000-02-25 | 2003-07-02 | 美国政府由(美国)卫生和福利部部长代表 | 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法 |
| JP2004509835A (ja) | 2000-03-06 | 2004-04-02 | ユニヴァーシティ オブ ケンタッキー リサーチ ファンデーション | 血液癌前駆細胞を障害する方法およびその関連化合物 |
| AU2001259792B2 (en) | 2000-03-29 | 2005-12-22 | The Ohio State University Research Foundation | Methods of blocking tissue destruction by autoreactive T cells |
| IL136511A0 (en) | 2000-06-01 | 2001-06-14 | Gavish Galilee Bio Appl Ltd | Genetically engineered mhc molecules |
| GB0025307D0 (en) | 2000-10-16 | 2000-11-29 | Celltech Chiroscience Ltd | Biological products |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| US7177912B1 (en) | 2000-12-22 | 2007-02-13 | Datacore Software Corporation | SCSI transport protocol via TCP/IP using existing network hardware and software |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US7514537B2 (en) | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| CA2445746C (en) | 2001-04-30 | 2012-09-18 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2003013598A2 (en) | 2001-08-09 | 2003-02-20 | Lam Dominic M K | Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| US7638326B2 (en) | 2002-01-03 | 2009-12-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20040242504A1 (en) | 2003-05-30 | 2004-12-02 | Vadim Ivanov | Novel composition and method for the treatment of hypertension |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| NZ543635A (en) | 2003-06-25 | 2008-05-30 | Crucell Holland Bv | Human C-type lectin: a suitable target molecule for binding molecules, particularly immunoconjugates, in the diagnosis, prevention and/or treatment of myeloid neoplastic diseases such as AML and CML |
| KR101531400B1 (ko) | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| WO2005023761A2 (en) | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| DE602004030586D1 (de) | 2003-09-15 | 2011-01-27 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| JP2007522447A (ja) | 2004-01-23 | 2007-08-09 | サノフィ パストゥール インコーポレイテッド | 細胞傷害性アッセイ |
| ES2653570T3 (es) | 2004-05-27 | 2018-02-07 | The Trustees Of The University Of Pennsylvania | Células presentadoras de antígeno artificiales novedosas y usos de las mismas |
| US7994298B2 (en) | 2004-09-24 | 2011-08-09 | Trustees Of Dartmouth College | Chimeric NK receptor and methods for treating cancer |
| WO2006060878A1 (en) | 2004-12-10 | 2006-06-15 | Peter Maccallum Cancer Institute | Methods and compositions for adoptive immunotherapy |
| US20060171929A1 (en) | 2005-01-31 | 2006-08-03 | The University Of Washington | Regulation of dendritic cell functions by the DCAL-2 receptor |
| US20110129412A1 (en) | 2005-06-02 | 2011-06-02 | Astrazeneca Ab | Antibodies Directed to CD20 and Uses Thereof |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| EP1795588A1 (en) | 2005-12-07 | 2007-06-13 | Cellerix, S.L. | Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease |
| WO2008045437A2 (en) | 2006-10-09 | 2008-04-17 | The General Hospital Corporation | Chimeric t-cell receptors and t-cells targeting egfrviii on tumors |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| JP2008228690A (ja) | 2007-03-23 | 2008-10-02 | Mitsukan Group Honsha:Kk | 甘味を有するタンパク質 |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| WO2008127735A1 (en) | 2007-04-13 | 2008-10-23 | Stemline Therapeutics, Inc. | Il3ralpha antibody conjugates and uses thereof |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| US20090088373A1 (en) | 2007-09-28 | 2009-04-02 | Gallo Richard L | Use of compositions to enhance innate immune response |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| US10059923B2 (en) | 2008-01-30 | 2018-08-28 | Memorial Sloan Kettering Cancer Center | Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors |
| US8379824B2 (en) | 2008-03-06 | 2013-02-19 | At&T Intellectual Property I, Lp | Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network |
| WO2010012829A1 (en) | 2008-07-31 | 2010-02-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Her2/neu specific t cell receptors |
| EP2318002A4 (en) | 2008-08-05 | 2012-11-28 | Univ Emory | USE OF MTOR INHIBITORS FOR INCREASING IMMUNE RESPONSES OF T CELLS |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| EP2365802B1 (en) | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
| EP2375897A4 (en) | 2009-01-14 | 2013-05-15 | Health Research Inc | METHOD AND COMPOSITIONS USING MTOR-INHIBITORS FOR IMPROVING IMMUNE REACTIONS |
| US9206440B2 (en) | 2009-01-23 | 2015-12-08 | Roger Williams Hospital | Viral vectors encoding multiple highly homologus non-viral polypeptides and the use of same |
| SG175166A1 (en) | 2009-04-17 | 2011-11-28 | Biogen Idec Inc | Compositions and methods to treat acute myelogenous leukemia |
| EP2483301A1 (en) | 2009-10-01 | 2012-08-08 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
| CN102665756A (zh) | 2009-10-01 | 2012-09-12 | Csl有限公司 | 费城染色体阳性白血病的治疗方法 |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US9133436B2 (en) | 2010-02-04 | 2015-09-15 | The Trustees Of The University Of Pennsylvania | ICOS critically regulates the expansion and function of inflammatory human Th17 cells |
| SE535129C2 (sv) | 2010-07-13 | 2012-04-24 | Bostik Ab | Komposition för vidhäftning av ett golvmaterial |
| CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| US9493740B2 (en) | 2010-09-08 | 2016-11-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered GD2-specific T cells |
| WO2012058460A2 (en) | 2010-10-27 | 2012-05-03 | Baylor College Of Medicine | Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies |
| EP2640750A1 (en) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| KR101400194B1 (ko) | 2010-12-01 | 2014-05-27 | 제일모직 주식회사 | 컬러필터용 감광성 수지 조성물 및 이를 이용한 컬러필터 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2651442B1 (en) | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| WO2012127464A2 (en) | 2011-03-23 | 2012-09-27 | Gavish-Galilee Bio Applications Ltd | Constitutively activated t cells for use in adoptive cell therapy |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| JP6082997B2 (ja) | 2011-04-01 | 2017-02-22 | メモリアル スローン−ケタリング キャンサー センター | Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体 |
| CN107188969B (zh) | 2011-04-08 | 2021-08-27 | 美国卫生和人力服务部 | 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
| NZ723731A (en) | 2011-04-08 | 2020-05-29 | Baylor College Medicine | Reversing the effects of the tumor microenvironment using chimeric cytokine receptors |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| PH12013502421A1 (en) | 2011-05-27 | 2014-01-06 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| CN103764668B (zh) | 2011-07-09 | 2016-08-17 | 加利福尼亚大学董事会 | 白血病干细胞靶向配体及应用方法 |
| ES2990023T3 (es) | 2011-07-25 | 2024-11-28 | Nationwide Childrens Hospital Inc | Productos de virus recombinantes y métodos para inhibición de la expresión de DUX4 |
| PE20141520A1 (es) | 2011-07-29 | 2014-11-17 | Univ Pennsylvania | Receptores coestimuladores de cambio |
| PT2748201T (pt) | 2011-08-23 | 2018-02-08 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas que ativam as células t |
| WO2013026839A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US9833476B2 (en) | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| SG11201400527XA (en) | 2011-09-16 | 2014-04-28 | Univ Pennsylvania | Rna engineered t cells for the treatment of cancer |
| US20140255363A1 (en) | 2011-09-16 | 2014-09-11 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013059593A1 (en) | 2011-10-20 | 2013-04-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd22 chimeric antigen receptors |
| KR101471647B1 (ko) | 2011-10-26 | 2014-12-11 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| WO2013063419A2 (en) | 2011-10-28 | 2013-05-02 | The Trustees Of The University Of Pennsylvania | A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| DK2794658T3 (en) | 2011-12-19 | 2017-06-19 | Synimmune Gmbh | BISPECIFIC ANTIBODY MOLECULE |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| EP2817330B1 (en) | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| MX2014010185A (es) | 2012-02-22 | 2014-11-14 | Univ Pennsylvania | Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion. |
| US20150086521A1 (en) | 2012-03-21 | 2015-03-26 | Erytech Pharma | Medicament for the Treatment of Acute Myeloid Leukemia (AML) |
| CA3209571A1 (en) | 2012-03-23 | 2013-09-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20130271355A1 (en) | 2012-04-13 | 2013-10-17 | Nokia Corporation | Multi-segment wearable accessory |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| EP4053162A1 (en) | 2012-05-18 | 2022-09-07 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| CN103483452B (zh) | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN104583230A (zh) | 2012-07-13 | 2015-04-29 | 宾夕法尼亚大学董事会 | 通过共同引入双特异性抗体增强car t细胞的活性 |
| EP2872617A4 (en) | 2012-07-13 | 2015-12-09 | Univ Pennsylvania | EPITOP SPREADING IN CONNECTION WITH CAR T CELLS |
| BR112015000310A2 (pt) | 2012-07-13 | 2017-06-27 | Univ Pennsylvania | conjugado droga-molécula, e, método para inibir o esgotamento do tecido saudável durante a terapia com células t car |
| JP6482461B2 (ja) | 2012-07-13 | 2019-03-13 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 投与に関する形質導入ｔ細胞の適合性の評価方法 |
| ES2778701T3 (es) | 2012-07-13 | 2020-08-11 | The Trustees Of The Univ Of Pennsylvania Center For Technology Transfer | Gestión de toxicidad para la actividad antitumoral de CAR |
| BR112015000657B1 (pt) | 2012-07-13 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | Uso de uma célula geneticamente modificada para expressar um car |
| PL2884999T3 (pl) | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
| US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
| CN102875685B (zh) | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
| US9365641B2 (en) | 2012-10-01 | 2016-06-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| WO2014124143A1 (en) | 2013-02-06 | 2014-08-14 | Anthrogenesis Corporation | Modified t lymphocytes having improved specificity |
| EP3744736A1 (en) | 2013-02-20 | 2020-12-02 | Novartis AG | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| SG11201505896YA (en) | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| CN103113470B (zh) | 2013-02-27 | 2015-04-22 | 四川大学 | 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途 |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2014172584A1 (en) | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
| KR102238226B1 (ko) | 2013-05-14 | 2021-04-09 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| CA3225453A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| ES2963718T3 (es) | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| ES2857226T3 (es) | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| CN107109420A (zh) | 2014-07-21 | 2017-08-29 | 诺华股份有限公司 | 使用cll－1嵌合抗原受体的癌症治疗 |
| US20170226495A1 (en) | 2014-07-21 | 2017-08-10 | Novartis Ag | Sortase molecules and uses thereof |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ |
| US20170274014A1 (en) | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
| US20170209492A1 (en) | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| JP6919118B2 (ja) | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| MY189028A (en) | 2014-08-19 | 2022-01-20 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
| CA2961636A1 (en) | 2014-09-17 | 2016-03-24 | Boris ENGELS | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN106973568B (zh) | 2014-10-08 | 2021-07-23 | 诺华股份有限公司 | 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途 |
| WO2016061368A1 (en) | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| IL303247A (en) | 2014-12-29 | 2023-07-01 | Novartis Ag | Methods for preparing cells expressing a chimeric receptor antigen |
| US11459390B2 (en) | 2015-01-16 | 2022-10-04 | Novartis Ag | Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| ES2876974T3 (es) | 2015-04-07 | 2021-11-15 | Novartis Ag | Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| CN108473957B (zh) | 2015-04-17 | 2024-07-16 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| JP7146632B2 (ja) | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| US11747346B2 (en) | 2015-09-03 | 2023-09-05 | Novartis Ag | Biomarkers predictive of cytokine release syndrome |
| MX2018003353A (es) | 2015-09-17 | 2018-09-17 | Novartis Ag | Terapias con celulas cart con una eficacia mejorada. |
| MA44140A (fr) | 2015-12-22 | 2021-05-19 | Dana Farber Cancer Inst Inc | Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse |
| JP2019500394A (ja) | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
| IL264486B2 (en) | 2016-07-28 | 2025-04-01 | Novartis Ag | Combination therapies of chimeric antigen receptors and PD-1 inhibitors |
| SG11201900885VA (en) | 2016-08-01 | 2019-02-27 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
-
2015
- 2015-07-21 CN CN201580050589.9A patent/CN107109420A/zh active Pending
- 2015-07-21 WO PCT/US2015/041337 patent/WO2016014535A1/en not_active Ceased
- 2015-07-21 KR KR1020177004392A patent/KR20170037625A/ko not_active Ceased
- 2015-07-21 SG SG10201913782UA patent/SG10201913782UA/en unknown
- 2015-07-21 CA CA2955465A patent/CA2955465A1/en not_active Abandoned
- 2015-07-21 MX MX2017001013A patent/MX2017001013A/es unknown
- 2015-07-21 BR BR112017000939A patent/BR112017000939A2/pt not_active IP Right Cessation
- 2015-07-21 RU RU2017105161A patent/RU2741120C2/ru active
- 2015-07-21 AU AU2015292811A patent/AU2015292811B2/en not_active Ceased
- 2015-07-21 JP JP2017503488A patent/JP6736540B2/ja not_active Expired - Fee Related
- 2015-07-21 AR ARP150102310A patent/AR101829A1/es unknown
- 2015-07-21 US US14/805,075 patent/US10568947B2/en active Active
- 2015-07-21 TW TW104123638A patent/TWI718992B/zh not_active IP Right Cessation
- 2015-07-21 EP EP15744448.0A patent/EP3171882A1/en not_active Withdrawn
- 2015-07-21 SG SG11201700418VA patent/SG11201700418VA/en unknown
-
2017
- 2017-01-15 IL IL250116A patent/IL250116B/en active IP Right Grant
- 2017-01-20 CO CONC2017/0000506A patent/CO2017000506A2/es unknown
-
2019
- 2019-12-27 US US16/728,557 patent/US20200215171A1/en not_active Abandoned
-
2020
- 2020-03-18 AU AU2020201939A patent/AU2020201939A1/en not_active Abandoned
- 2020-07-15 JP JP2020121501A patent/JP2020185001A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160051651A1 (en) | 2016-02-25 |
| IL250116A0 (en) | 2017-03-30 |
| CO2017000506A2 (es) | 2017-06-30 |
| IL250116B (en) | 2021-06-30 |
| RU2741120C2 (ru) | 2021-01-22 |
| CN107109420A (zh) | 2017-08-29 |
| MX2017001013A (es) | 2018-02-21 |
| US10568947B2 (en) | 2020-02-25 |
| AR101829A1 (es) | 2017-01-18 |
| KR20170037625A (ko) | 2017-04-04 |
| EP3171882A1 (en) | 2017-05-31 |
| AU2020201939A1 (en) | 2020-04-09 |
| AU2015292811A1 (en) | 2017-02-02 |
| US20200215171A1 (en) | 2020-07-09 |
| SG10201913782UA (en) | 2020-03-30 |
| JP2017522879A (ja) | 2017-08-17 |
| TWI718992B (zh) | 2021-02-21 |
| RU2017105161A (ru) | 2018-08-21 |
| JP6736540B2 (ja) | 2020-08-05 |
| WO2016014535A1 (en) | 2016-01-28 |
| JP2020185001A (ja) | 2020-11-19 |
| AU2015292811B2 (en) | 2019-12-19 |
| TW201619380A (zh) | 2016-06-01 |
| SG11201700418VA (en) | 2017-02-27 |
| CA2955465A1 (en) | 2016-01-28 |
| BR112017000939A2 (pt) | 2017-11-14 |